 |
|
|
|
This month we would like to know...
Egrifta (tesamorelin) was recently FDA-approved to treat HIV-associated lipodystrophy (aka, visceral adipose tissue [VAT]), which will be available in January 2011. VAT has been associated with adverse cardiovascular outcomes. How is your health-system covering or planning on covering this injectable drug product?
| a) |
We will be/are covering it as a medically necessary drug if patient's meet criteria for use. |
| |
|
| b) |
We will be/are covering it as a medically necessary drug for all HIV patients. |
| |
|
| c) |
We will not be covering it at all since it is a cosmetic product. |
| |
|
| d) |
We have not yet decided how to cover this product. |
| |
|
|
|
|
|
Contact Us
Click here to contact a Formulary editor.
Click here to contact a Formulary sales representative.
Click here to learn about direct mail, reprints and classifieds in Formulary.
Formulary
Digital Edition
Click here to view the current edition.
Click here to subscribe. |
|
|
|
|
|
|
| |
Paricalcitol found to reduce albuminuria in type 2 diabetes
In a multinational, placebo-controlled, double-blind trial, the selective vitamin D receptor activator paricalcitol (Zemplar, Abbott Laboratories), at doses of 1 µg or 2 µg daily, reduced albuminuria in patients with type 2 diabetes, who were already being treated with renin-angiotensin-aldosterone system inhibitors. This research was published online November 4 in The Lancet, HealthDay News reported. More... |
|
Manufacturer agrees to withdraw propoxyphene from the market
Xanodyne Pharmaceuticals has agreed to withdraw propoxyphene (Darvon and Darvocet) from the US market at the request of FDA. FDA also has informed generic manufacturers of Xanodyne’s decision, and they will be removing their propoxyphene-containing products from the market as well. More... |
|
| |
| |
| Top 5 Web Stories |
| Focus on lurasidone: A new atypical antipsychotic for the treatment of schizophrenia |
| Attention deficit hyperactivity disorder: More than a child's disease |
| FDA Actions in Brief November 2010 (Latuda, Ofirmev, Cymbalta, Botox, Pradaxa, Afinitor, Teflaro, Herceptin, Kapvay) |
| Olmesartan medoxomil, amlodipine, and hydrochlorothiazide (Tribenzor): A new 3-drug combination product for the treatment of hypertension |
| FDA Pipeline Preview, November 2010 (Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol extended-release oral analgesic, AVP-21D9, 1% tenofovir vaginal gel, AFM 13, hGH-CTP, Rozrolimupab, Nefecon, SB1518 JAK2 inhibitor) |
|
|
|
|
|
|
|
|
|
|
| |
